title: Progression of macular ischemia following intravitreal bevacizumab.
abstract: A 37-year-old woman with bilateral obliterative retinal vasculitis and macular ischemia received intravitreal bevacizumab for rapidly progressive neovascularization of the optic disc and vitreous hemorrhage in the left eye. One week after treatment, she presented with central scotoma and fluorescein angiography revealed increased parafoveal capillary dropout and progressive macular ischemia in the treated eye.
authors.affiliation: Retina Division, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
authors.forename: E Jason
authors.initials: EJ
authors.lastname: Sabet-Peyman
authors.forename: Florian M A
authors.initials: FM
authors.lastname: Heussen
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Thorne
authors.forename: Heather
authors.initials: H
authors.lastname: Casparis
authors.forename: Sayjal J
authors.initials: SJ
authors.lastname: Patel
authors.forename: Diana V
authors.initials: DV
authors.lastname: Do
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018450:Disease Progression; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D007267:Injections; D007511:Ischemia / Q000503:physiopathology*; D017075:Laser Coagulation; D008266:Macula Lutea / Q000098:blood supply*; D008269:Macular Edema / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D009898:Optic Disk / Q000098:blood supply*; D031300:Retinal Vasculitis / Q000503:physiopathology; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity; D014822:Vitreous Body; D014823:Vitreous Hemorrhage / Q000188:drug therapy
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab